Skip to content

EDESA BIOTECH, INC.: 10-Q filed 2020-05-15

What EDESA BIOTECH, INC. reported in its quarterly report filed 2020-05-15 (fiscal Q2 2020): 32 published measures, 93 facts as tagged in accession 0001654954-20-005548.

This filing

Form
10-Q (quarterly report)
Filed
2020-05-15
Fiscal period
fiscal Q2 2020
Accession
0001654954-20-005548 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All EDESA BIOTECH, INC. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

PeriodValueUnitDays
At 2020-03-317,632,624USD
At 2019-09-305,717,764USD

Total liabilities

Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.

PeriodValueUnitDays
At 2020-03-31701,681USD
At 2019-09-30461,634USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

PeriodValueUnitDays
At 2020-03-316,930,943USD
At 2019-12-314,233,686USD
At 2019-09-305,256,130USD
At 2019-03-312,772,359USD
At 2018-12-313,214,490USD
At 2018-09-303,550,145USD

Cash and cash equivalents

Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.

PeriodValueUnitDays
At 2020-03-316,989,930USD
At 2019-09-305,030,583USD
At 2019-03-313,042,141USD
At 2018-09-303,730,230USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

PeriodValueUnitDays
2020-01-01 to 2020-03-31-1,489,636USD91
2019-10-01 to 2020-03-31-2,583,969USD183
2019-01-01 to 2019-03-31-528,830USD90
2018-10-01 to 2019-03-31-893,679USD182

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

PeriodValueUnitDays
2019-10-01 to 2020-03-31-1,960,159USD183
2018-10-01 to 2019-03-31-781,228USD182

Capital expenditure payments

Cash payments to acquire property, plant and equipment. This taxonomy concept does not capture every form of investment or acquisition.

PeriodValueUnitDays
2019-10-01 to 2020-03-31825USD183
2018-10-01 to 2019-03-311,504USD182

Revenue

Revenue under this specific accounting concept. A missing value is not zero; filers can use other revenue concepts.

PeriodValueUnitDays
2020-01-01 to 2020-03-31110,516USD91
2019-10-01 to 2020-03-31218,316USD183
2019-01-01 to 2019-03-310USD90
2018-10-01 to 2019-03-310USD182

Financing cash flow

Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.

PeriodValueUnitDays
2019-10-01 to 2020-03-313,891,801USD183
2018-10-01 to 2019-03-310USD182

Investing cash flow

Net cash from investing activities, including asset purchases, disposals and investment transactions. This differs from capital expenditure payments alone.

PeriodValueUnitDays
2019-10-01 to 2020-03-3142,359USD183
2018-10-01 to 2019-03-31-1,504USD182

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

PeriodValueUnitDays
At 2020-03-31-9,318,584USD
At 2019-09-30-6,734,615USD

Income tax expense or benefit

Current and deferred income tax expense or benefit for continuing operations. This accounting expense differs from cash taxes paid.

PeriodValueUnitDays
2020-01-01 to 2020-03-310USD91
2019-10-01 to 2020-03-31800USD183
2019-01-01 to 2019-03-310USD90
2018-10-01 to 2019-03-310USD182

Net property, plant and equipment

Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.

PeriodValueUnitDays
At 2020-03-3125,110USD
At 2019-09-3073,058USD

Share-based compensation expense

Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.

PeriodValueUnitDays
2020-01-01 to 2020-03-31380,000USD91
2019-10-01 to 2020-03-31388,775USD183
2019-01-01 to 2019-03-3113,446USD90
2018-10-01 to 2019-03-3124,880USD182

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

PeriodValueUnitDays
2020-01-01 to 2020-03-31-1,516,252USD91
2019-10-01 to 2020-03-31-2,621,934USD183
2019-01-01 to 2019-03-31-540,778USD90
2018-10-01 to 2019-03-31-946,519USD182

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

PeriodValueUnitDays
At 2020-03-317,426,022USD
At 2019-09-305,644,706USD

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

PeriodValueUnitDays
At 2020-03-31578,938USD
At 2019-09-30461,634USD

Operating expenses

Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.

PeriodValueUnitDays
2020-01-01 to 2020-03-311,626,768USD91
2019-10-01 to 2020-03-312,840,250USD183
2019-01-01 to 2019-03-31540,778USD90
2018-10-01 to 2019-03-31946,519USD182

Cost of revenue

Costs attributed to goods produced and sold and services provided during the period. This is not the sum of every operating expense.

PeriodValueUnitDays
2020-01-01 to 2020-03-3110,037USD91
2019-10-01 to 2020-03-3113,815USD183
2019-01-01 to 2019-03-310USD90
2018-10-01 to 2019-03-310USD182

Research and development expense

Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.

PeriodValueUnitDays
2020-01-01 to 2020-03-31502,814USD91
2019-10-01 to 2020-03-311,030,812USD183
2019-01-01 to 2019-03-31111,702USD90
2018-10-01 to 2019-03-31369,093USD182

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

PeriodValueUnitDays
At 2020-03-318,859,159shares
At 2019-09-307,504,468shares

Additional paid-in capital

Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.

PeriodValueUnitDays
At 2020-03-311,880,721USD
At 2019-09-30327,768USD

Accumulated other comprehensive income or loss

Cumulative other comprehensive items after tax, such as translation and unrealized hedging or securities effects. These amounts have not passed through net income.

PeriodValueUnitDays
At 2020-03-31-363,868USD
At 2019-09-30-342,074USD

Operating lease right-of-use asset

Carrying amount of the right to use leased assets under operating leases. It reflects discounted remaining payments, not the value of the underlying property.

PeriodValueUnitDays
At 2020-03-31181,492USD
At 2019-09-300USD

Operating lease liability

Present value of remaining operating lease payments. Discount-rate choices and lease terms affect the amount; it is not the sum of undiscounted future rent.

PeriodValueUnitDays
At 2020-03-31185,439USD

Gross property, plant and equipment

Cost of property, plant and equipment before accumulated depreciation. Historical cost does not indicate current value or replacement cost.

PeriodValueUnitDays
At 2020-03-3150,724USD
At 2019-09-3050,842USD

Accumulated depreciation on property, plant and equipment

Cumulative depreciation, depletion and amortization recorded against property, plant and equipment. It measures cost allocation to date, not physical wear or market value.

PeriodValueUnitDays
At 2020-03-3133,840USD
At 2019-09-3029,194USD

Comprehensive income or loss

Net income plus other comprehensive income after tax. It includes unrealized items that net income excludes and is not a cash measure.

PeriodValueUnitDays
2020-01-01 to 2020-03-31-1,529,544USD91
2019-10-01 to 2020-03-31-2,605,763USD183
2019-01-01 to 2019-03-31-455,577USD90
2018-10-01 to 2019-03-31-802,666USD182

General and administrative expense

General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.

PeriodValueUnitDays
2020-01-01 to 2020-03-311,113,917USD91
2019-10-01 to 2020-03-311,795,623USD183
2019-01-01 to 2019-03-31429,076USD90
2018-10-01 to 2019-03-31577,426USD182

Depreciation expense

Depreciation recognized for the period under this concept. It is a noncash allocation of asset cost and may exclude amortization and depletion reported elsewhere.

PeriodValueUnitDays
2020-01-01 to 2020-03-312,651USD91
2019-10-01 to 2020-03-315,054USD183
2019-01-01 to 2019-03-31504USD90
2018-10-01 to 2019-03-31916USD182

Nonoperating income or expense

Total nonoperating income or expense, which can include interest, investment results and other items. A positive value is not operating profit.

PeriodValueUnitDays
2020-01-01 to 2020-03-3126,616USD91
2019-10-01 to 2020-03-3138,765USD183
2019-01-01 to 2019-03-3111,948USD90
2018-10-01 to 2019-03-3152,840USD182

Change in accounts receivable

The cash flow adjustment for the change in receivables during the period. A positive value under this concept means receivables grew and reduced operating cash flow.

PeriodValueUnitDays
2019-10-01 to 2020-03-31-127,146USD183
2018-10-01 to 2019-03-3116,357USD182

Inspect the source

Entity
EDESA BIOTECH, INC. / CIK 0001540159
Captured
2026-09-20T09:17:32.413Z
SEC response SHA-256
0f44de1ccf1eff46a1af17dc21d4a3bb38216bbf46e813f5a136d29e08bfd65d

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python
import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001540159.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))